Electronic Patient‐Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second‐Line Chemotherapy: A Multicenter Observational Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.71161 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yuki Takumoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Quality of Life, Patient Reported Outcome Measures, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Public Health Research Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Patients' QoL scores during chemotherapy are generally measured during hospital visits. However, patients frequently recover from AEs before hospital arrival. This study continuously assessed each chemotherapy's impact on patients' QoL scores during hospital visits and at home using an electronic device (ePRO).
Methods
This multicenter, prospective observational study was conducted in 29 Japanese hospitals. Patients were treated with liposomal irinotecan, fluorouracil, and levoleucovorin (Nal‐IRI + 5‐FU/LV), gemcitabine and nab‐paclitaxel (GnP), or gemcitabine (GEM) as second‐line chemotherapy for unresectable pancreatic cancer. All respondents used ePRO to answer several QoL questionnaires on Days 1, 2, 4, 6, 8, and 11 following chemotherapy administration. The primary endpoint was the EQ‐5D‐5L index value, and the secondary endpoints were AE frequency and the EORTC QLQ‐C30.
Results
The analysis included 67 participants. The mean ± SD QoL scores of the Nal‐IRI + 5‐FU/LV and GnP arms varied from 0.803 ± 0.142 to 0.678 ± 0.247 and 0.872 ± 0.077 to 0.726 ± 0.185, respectively, over the evaluation period. The highest and lowest QoL scores were observed around the chemotherapy administration and approximately 1 week after the chemotherapy administration, respectively, in both arms.
Conclusions
Patients' QoL score assessment over time by ePRO revealed QoL score trends, which emphasized the importance of QoL management outside of hospital visits for each chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Saitama, Japan.
- Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
- Department of Gastroenterology, Kanagawa Cancer Center, Kanagawa, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Yuki Takumoto, Makoto Ueno, Kenji Ikezawa, Naohiro Okano, Hiroto Narimatsu
Förderung
- Public Health Research Foundation
Zitieren
APA
Takumoto, Y., Ohba, A., Terashima, T., Ueno, M., Ikezawa, K., Okano, N., Okusaka, T., Morizane, C., Ikeda, M., Ozaka, M., Narimatsu, H., Akazawa, M., Shiroiwa, T., & Furuse, J. (2025). Electronic Patient‐Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second‐Line Chemotherapy: A Multicenter Observational Study. Cancer Medicine. https://doi.org/10.1002/cam4.71161
Vancouver
Takumoto Y, Ohba A, Terashima T, Ueno M, Ikezawa K, Okano N, et al. Electronic Patient‐Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second‐Line Chemotherapy: A Multicenter Observational Study. Cancer Medicine. 2025. doi:10.1002/cam4.71161
BibTeX
@article{Takumoto2025,
author = {Takumoto, Yuki and Ohba, Akihiro and Terashima, Takeshi and Ueno, Makoto and Ikezawa, Kenji and Okano, Naohiro and Okusaka, Takuji and Morizane, Chigusa and Ikeda, Masafumi and Ozaka, Masato and Narimatsu, Hiroto and Akazawa, Manabu and Shiroiwa, Takeru and Furuse, Junji},
title = {Electronic Patient‐Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second‐Line Chemotherapy: A Multicenter Observational Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71161}
}
EUVIMED